Book I 1325 majority of readers will be looking at individual chapters or using this as a reference text, thus repetition is inevitable to ensure comprehensiveness in the individual chapters. The chapter by Petros and Peters on dose intensity to overcome drug resistance deals with resistance more by implication than by direct reference to resistance data, and avoids dealing with the controversies. The chapters on molcular mechanisms of anti-oestrogen resistance and tamoxifen metabolism from the groups Jordon and Osborne unfortunately lack the more recent data on non-isomerisable tamoxifen derivatives, which is an important component of the current interpretation of data from this field. This illustrates a more general point: throughout there are almost no references beyond 1992. The two chapters on progestins and anti-progestins have few data on resistance to these compounds, but they provide a useful summary of data from in vitro models.
1325 majority of readers will be looking at individual chapters or using this as a reference text, thus repetition is inevitable to ensure comprehensiveness in the individual chapters. The chapter by Petros and Peters on dose intensity to overcome drug resistance deals with resistance more by implication than by direct reference to resistance data, and avoids dealing with the controversies. The chapters on molcular mechanisms of anti-oestrogen resistance and tamoxifen metabolism from the groups Jordon and Osborne unfortunately lack the more recent data on non-isomerisable tamoxifen derivatives, which is an important component of the current interpretation of data from this field. This illustrates a more general point: throughout there are almost no references beyond 1992. The two chapters on progestins and anti-progestins have few data on resistance to these compounds, but they provide a useful summary of data from in vitro models.
Part 3, dealing with chemotherapeutic drugs, has substantial overlap throughout some of the chapters on multi-drug resistance and the importance of MDRI Weisenthal provides a valuable discussion for those interested in in vitro tests to predict breast cancer sensitivity to these agents. This particular chapter is unusual in this book in that the tables are poorly annotated and reduced in value as a result of that.
The last two chapters on approaches to reversing multidrug resistance could have been excluded since they are highly repetitive of other chapters in this section.
The three chapters on chemohormonal interactions deal with separate issues: (i) the relationship between cell kinetics and hormonal receptors and their utility for treatment selection; (ii) hormonal synchronisation before chemotherapy, reflecting that this has proven to be uniformly without benefit; (iii) an extensive laboratory-orientated discussion of the interactions of chemo-and hormonal therapy in cell culture. It In the first paper, Miguel Beato reviews our knowledge of how steroid hormones modulate the expression of a variety of genes by binding to hormone-responsive elements of DNA or interacting with various transcription factors to influence signal transduction pathways. The interactions of hormone, receptor and the several other factors involved are complex, and an important mechanism may involve the hormone itself changing the chromatin structure. Similarly, the concept of antihormones occupying the receptor site, thereby preventing hormone action, may be only one of several possible mechanisms, and specific binding sites for antihormones may also exist.
Etienne-Emile Baulieu points out that non-genomic mechanisms of hormone action are also important. Effects of membrane interaction and changes in membrane structure have been noted, and the role of binding proteins influencing intracellular machinry is still unclear. There are several examples of progestagens influencing biochemical activity at the membrane and also modulating calcium entry into cells.
Bruce McEwen discusses neural effects of steroids. Apart from their well-known role in reproduction, they also affect pain perception, cognitive function and mood. Oestradiol induces choline acetyltransferase activity in the forebrain and reduces synapse density. The mechanism is unclear, only a few classical oestrogen receptors exist in pyramidal cells, although the oestrogen receptor may perhaps be atypical. Interestingly, hormone replacement therapy (HRT) has been reported to ameliorate the symptoms of Alzheimer's disease.
Michael Schumacher discusses the role of sex steroids in nerve repair. Progesterone is actively synthesised and metabolised in brain tissue, and the hormone or its metabolites may accelerate the repair of myelin sheaths after injury.
There is a lesser incidence ofcoronary heart disease in women than in men. It is likely that oestradiol is a major factor, the mechanism, in part, involving lipoprotein changes. Francis Bayard's paper points out that direct effects on the blood vessel wall should not be ruled out. The enzymes that synthesise and metabolise oestrogens are present on the vascular wall, and their effects on cytokines, growth factors and vasoregulatory molecules are probably involved in the pathogenesis of arteriosclerosis. Following this theme, Marie Foegh presents data on transplant arteriosclerosis, which is a major clinical problem. Oestradiol profoundly influences the immune system and it is notable that women are more susceptible to autoimmune diseases than men are. Oestrogens enhance the differentiation and maturation of lymphocytes and diminish suppressor T-cell function. In transplant patients, HRT is an unfavourable factor.
However, in an animal modeL oestradiol inhibited myointimal hyperplasia and prevented entry of macrophages, which is probably the initiating factor. Thus, oestradiol has complex effects on thevascularsystem, still not well defined orunderstood.
Madge Vickers reports that coronary heart disease is the most common cause of death in post-menopausal women and that some protection is given by HRT. She describes a proposed epidemiological study of users of HRT in the UK and elsewhere in Europe, which would address many of the unanswered questions, including the effect of HRT on vascular disease. The problems with such a trial are considerable (e.g. changing fashions in dose, type of steroid, route of administration) but if the trial were postponed, no answer would ever be forthcoming.
Torbjorn Prostate cancer is common in older men, and testosterone is closely involved in the development and growth of these tumours. Using prostate cancer cell lines in vitro, Luigi Castagnetta had examined the role of oestradiol and showed that some cell lines are inhibited in their growth by oestradiol, whereas others are stimulated. This hormone may act synergistically with testosterone. The mechanism by which androgens act does not seem to involve an androgen receptor. Oestrogen receptors were clearly shown to be present in prostate cancer cells and so the mechanism presumably involves activation of oestrogen receptor and transforming growth factor beta, as growth can be blocked by antibodies to this growth factor.
What emerges from this meeting is that oestrogens and androgens have multiple effects on a variety of tissues, not just those classically recognised and defined as 'target tissues'. The brain, cardiovascular system, muscle, bone, the immune system and many other tissues are apparently influenced, albeit subtly in some cases, by sex steroids. Equally striking is the emerging concept that hormones may exert their effects not only by direct interaction with receptor proteins, which then activate the appropriate biosynthetic events, but also by modulating a large variety of intra-and extracellular control mechanisms which, in turn, can control the signalling mechanisms. We are only just starting to discover the extent and complexity of this aspect of hormone action. T1his is true, of course, but with the introduction of combinatorial chemistry, for example, and user-friendly computer programs to study receptor-drug interactions at the atomic level one can predict that this will be an important future approach. Indeed, drugs are already in the clinic that have been uncovered by these methods and, should they prove to be superior to analogues discovered by screening or biochemical approaches, then one would expect programs dedicated to discovering agents acting on abnormal pathways in cancer such as the work described on the active site of protein kinase C or o6 methyltransferase to expand rapidly. Apart from some interesting findings with suramin, the middle of the book is disappointing in that it deals with rather mundane approaches involving cisplatin and other conventional anti-cancer agents and attempts to improve their selectivity by the design of analogues, the use of combinations or attempts to overcome resistance. The Cancer Chemotherapy Annual deals with these approaches each year and this volume adds nothing that is either new or exciting. The book perks up towards the end with some interesting presentations on the bisphosphonates, bioreductives, steroid carriers of BCNU and new agents for BNCT (boron neutron capture therapy), an old approach but one which is now being reapplied clinically on the basis of sound scientific data.
VHT

T Connors
Cancer of the Bat (4th edn) Edited by WL Donegan and JS Spratt WB Saunders Company: 1995, 860 pp. £115, ISBN 0-7216-4694-8 This is a comprehensive text that is clear and well written by the contributors. Many of the chapters are written by the editors and draw on their experience as well as being well referenced.
The book is well organised and begins with an entertaining historical account of breast cancer, tracing the origins of treatment to the earliest records available.
The subsequent chapters then describe the basic sciences of anatomy, physiology and pathology of the breast and serve as a useful source of reference. The often confusing area of benign breast disorders and the overlap with pathology is then tackled and clarified in chapters 6 and 7, with a helpful description of abnormalities of normal breast development and involution (ANDI).
The text then describes the epidemiology and aetiology of breast cancer in a clear and concise way. Chapter 10 describes the diagnosis of breast cancer and draws on the author's (Donegan) own experience. The section is well illustrated with line drawings demonstrating clear examination and surgical techniques. The following chapter (11) similarly gives an account of imaging, again combining experience with referenced data. The author (Moskowitz) writes authoritatively, describing the development of imaging techniques and screening. This section also describes ultrasound needle localisation techniques as well as other
